Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Tecfidera-Generic (dimethyl fumarate) is an oral Nuclear factor erythroid-derived 2 (Nrf2) pathway activator. It is approved for the treatment of patients with relapsing forms of multiple sclerosis.
Lead Product(s): Dimethyl Fumarate
Therapeutic Area: Neurology Product Name: Tecfidera-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 19, 2023
Details:
The agreement aims for the commercialisation of HIPRA's mRNA COVID-19 vaccine, Bimervax, which combines a part of the SARS-CoV-2 virus spike protein with an adjuvant, in the United Kingdom.
Lead Product(s): Recombinant, Adjuvanted Covid-19 Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Bimervax
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Laboratorios HIPRA
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement August 04, 2023
Details:
Teriflunomide, an immunomodulatory agent with anti-inflammatory properties, inhibits dihydroorotate dehydrogenase, a mitochondrial enzyme involved in de novo pyrimidine synthesis. It is indicated for the treatment of relapsing forms of multiple sclerosis.
Lead Product(s): Teriflunomide
Therapeutic Area: Neurology Product Name: Aubagio-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 13, 2023
Details:
Lurasidone hydrochloride is a, oral atypical antipsychotic, full antagonist at dopamine D2 and serotonin 5-HT2A and 5-HT7 receptors, it is a first-line treatment option for the management of schizophrenia in adults and adolescents.
Lead Product(s): Lurasidone Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: Lurasidone-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 21, 2023
Details:
Plerixafor Injection is a hematopoietic stem cell mobilizer used in combination with granulocyte-colony stimulating factor in patients with non-Hodgkin's lymphoma or multiple myeloma.
Lead Product(s): Plerixafor
Therapeutic Area: Oncology Product Name: Mozobil-Generic
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 10, 2022
Details:
Carmustine is an anti-cancer ("antineoplastic") chemotherapy drug classified as an alkylating agent. It works by helping to halt the growth of cancer cells (cancer cell division).
Lead Product(s): Carmustine
Therapeutic Area: Oncology Product Name: Carmustine-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 23, 2022
Details:
Myovant will continue to lead the global development of Orgovyx (relugolix) and provide product supply to Accord. Accord will be responsible for certain local clinical development, commercialization for its territories, and has the option to manufacture relugolix in future.
Lead Product(s): Relugolix
Therapeutic Area: Oncology Product Name: Orgovyx
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Myovant Sciences
Deal Size: $140.5 million Upfront Cash: $50.0 million
Deal Type: Licensing Agreement May 09, 2022
Details:
Through this partnership with Foresee on the launch of CAMCEVI, Accord BioPharma with razor sharp focus on specialty pharmaceuticals, which will go beyond biology to bring more access to high-quality medicines to patients across the U.S.
Lead Product(s): Leuprolide Acetate
Therapeutic Area: Oncology Product Name: Camcevi
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Foresee Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership April 04, 2022
Details:
CAMCEVI is the first-ever ready-to-inject sterile formulation of leuprolide mesylate for subcutaneous injection that comes in a pre-filled syringe with no mixing required. In an open-label, single-arm study of 137 adults who received 42mg of CAMCEVI on Day 0 and Week 24.
Lead Product(s): Leuprolide Mesylate
Therapeutic Area: Oncology Product Name: Camcevi
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 31, 2022
Details:
Sondelbay (teriparatide), is a self-administered, once-a-day subcutaneous injection for patients with osteoporosis using a pen device, is indicated for treatment of osteoporosis.
Lead Product(s): Teriparatide
Therapeutic Area: Musculoskeletal Product Name: Sondelbay
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 28, 2022